Melanoma Drugs Flashcards
Chemo to treat malignant melanoma
Dacarbazine (alkylating agent)
MOA of ipilimumab
Recombinant monoclonal antibody that binds to CTLA-4 which serves as an immune checkpoint, blocks ligands CD80 and CD86 from binding therefore potentiating Tcell immune response
Side effect of ipilimumab
Priuritis Nausea and vomiting Diarrhoea Decreased appetite Abdominal pain Colitis Hepatitis
When can you use ipilimumab
Advanced malignant melanoma not previously treated or after prior therapy
How much does ipilimumab cost for 1 dose
£25,000
MOA of vemurafenib
BRAF kinase inhibitor (BRAF is a gene that’s mutated glutamine for valine at position 600 in 60% of melanomas- becomes constitutively active)
Side effects of vemurafenib
Fatigue Joint pain Pruritus Rash Sensitive to sun Squamous cell carcinomas Blistering skin Nausea Alopecia
Extra information on vemurafenib
Take with food
Metabolised by CYP450 so many drug interactions
Place in therapy for vemurafenib
Advanced malignant melanoma with BRAF V600 mutation
What is dabrafenib
BRAF inhibitor
Side effects of dabrafenib
Rash Headache Nausea and vom Diarrhoea Joint pain Uveitis Cutaneous squamous cell carcinoma
Extra info on dabrafenib
Take on empty stomach
Drug interactions as metabolised by CYP450
MOA of pembrolizumab
Binds to PD-1 of T cells preventing PD-L1 and PD-L2 from binding therefore activating immune response against tumour
Side effects of pembrolizumab
Cough
Fatigue
Rash
Immune type pnemonitis, colitis, hepatitis
Place in therapy of pembrolizumab
Advanced malignant melanoma without BRAFV600 first line and second line in patients with BRAF mutation
